Compounds > sk&f 97541
Page last updated: 2024-09-20

sk&f 97541

Description

3-aminopropyl(methyl)phosphinic acid: structure given in first source; GABA-A receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5230
CHEMBL ID112710
SCHEMBL ID341867
MeSH IDM0187228

Synonyms (57)

Synonym
3-aminopropyl-methylphosphinic acid
gtpl1080
skf-97,541
LOPAC0_000098
NCGC00015015-01
lopac-a-196
NCGC00024562-01
tocris-0379
BPBIO1_001014
BIOMOL-NT_000257
(3-aminopropyl)(methyl)phosphinic acid
bdbm24185
chembl112710 ,
3-aminopropylphosphinic derivative, 2
cgp35024
PDSP2_001467
cgp 35024
PDSP1_001483
NCGC00024562-03
sk&f 97541
phosphinic acid, (3-(aminopropyl)methyl)-
3-apmpa
(3-(aminopropyl)methyl)phosphinic acid
skf-97541
c4h12no2p
NCGC00024562-02
skf 97541 hydrochloride
127729-35-5
3-aminopropyl(methyl)phosphinic acid
L000069
cgp-35024
AKOS005468710
skf 97541
skf97541
STK538161
(3-aminopropyl)methylphosphinic acid
CCG-204193
NCGC00015015-03
NCGC00015015-05
NCGC00015015-02
NCGC00015015-04
SCHEMBL341867
NHVRIDDXGZPJTJ-UHFFFAOYSA-N
3-aminopropylmethylphosphinic acid
J-005534
phosphinic acid, (3-aminopropyl)methyl-
SR-01000076225-3
sr-01000076225
DTXSID80925969
HB0954
skf-97541;skf97541;cgp 35024;cgp-35024;cgp35024
Q7390605
QD7 ,
(r)-(3-aminopropyl)methylphosphinic acid
phosphinic acid, p-(3-aminopropyl)-p-methyl-
sk f 97541
3-aminopropyl(methyl)phosphinicacidhcl

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ThrombopoietinHomo sapiens (human)Potency19.95260.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency5.01190.001318.074339.8107AID926; AID938
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency7.94330.00106.000935.4813AID944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid type B receptor subunit 2Rattus norvegicus (Norway rat)IC50 (µMol)0.00800.00001.01016.8100AID71394; AID71401
Gamma-aminobutyric acid type B receptor subunit 2Rattus norvegicus (Norway rat)Ki0.03300.00510.06830.2200AID1798404
Gamma-aminobutyric acid type B receptor subunit 1Rattus norvegicus (Norway rat)IC50 (µMol)0.01070.00001.05326.8100AID71394; AID71401
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)Kb0.80000.80003.033310.0000AID406571
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
gamma-aminobutyric acid signaling pathwayGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
chemical synaptic transmissionGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
modulation of chemical synaptic transmissionGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
regulation of membrane potentialGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
chloride transmembrane transportGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
GABA-A receptor activityGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
protein domain specific bindingGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
GABA-gated chloride ion channel activityGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
identical protein bindingGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
protein-containing complex bindingGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
neurotransmitter receptor activityGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
chloride channel activityGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
presynaptic membraneGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
postsynaptic membraneGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
glutamatergic synapseGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
GABA-ergic synapseGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
chloride channel complexGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
GABA-A receptor complexGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
transmembrane transporter complexGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
neuron projectionGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
synapseGamma-aminobutyric acid receptor subunit rho-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1798404[3H]GABA Filtration Binding Assay (Ki) and FLIPR Assay for Agonism (EC50) from Article 10.1021/jm701425k: \\Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.\\2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID30360Inhibition of [3H]- N-6-CA binding to Adenosine A1 receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID339810Intrinsic activity at human recombinant GABAB receptor expressed in CHO-K1 cells assessed as inhibition of intracellular calcium release by FLIPR relative to GABA2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID142909Inhibition of [3H]CMD binding to muscarinic ACh receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID626682Agonist activity against human GABAB receptor expressed in HEK cells assessed as increase in cytoplasmic calcium level2011Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21
Discovery of a novel potent GABA(B) receptor agonist.
AID406571Antagonist activity at human GABAc Rho1 receptor expressed in Xenopus oocytes assessed as whole cell current production by two electrode voltage clamp method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Novel gamma-aminobutyric acid rho1 receptor antagonists; synthesis, pharmacological activity and structure-activity relationships.
AID152090Inhibition of [3H]- naloxone binding to mu-opiate receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID41898Inhibition of [3H]- DHA binding to Beta adrenergic receptor1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID71997Inhibition of [3H]muscimol binding to GABA-A receptor of rat cortex1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID72586Inhibition of [3H]- muscimol binding to Gamma-aminobutyric acid A (GABA-A) receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID3453Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID88556The compound was tested for blockade of the monosynaptic reflexes in the hemisected neonatal spinal cord1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID175515Deterioration of rotarod performance of rats 0.5-1 hour after subcutaneous administration of compound1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID36317Inhibition [3H]- prazosin binding to Alpha-1 adrenergic receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID35778Inhibition of [3H]- clonidine binding to Alpha-2 adrenergic receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID339809Agonist activity at human recombinant GABABreceptor expressed in CHO-K1 cells assessed as inhibition of intracellular calcium release by FLIPR2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID196573The compound was tested for inhibition of release of [3H]GABA from rat cortical slices after electrical stimulation.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID5134Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID71401Inhibition of [3H]CGP-27492 binding to Gamma-aminobutyric acid type B receptor of rat cortex1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID175288Enhanced electrically induced release of [3H]GABA from rat cortical slices; agonist1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists.
AID175653Deterioration of rotarod performance of rats 1.-2 hour after subcutaneous administration of compound1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID211502Inhibition of [3H]-substance P binding to Tachykinin receptor 1 at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID71258Inhibition of [3H]-baclofen binding to Gamma-aminobutyric acid type B receptor of cat cerebellum1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID71394Inhibition of binding of [3H]CGP-27492 to gamma-aminobutyric acid type B receptor of rat cortex.1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists.
AID87687Inhibition of [3H]- doxepine binding to histamine 1 receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID339808Displacement of [3H]GABA from GABABreceptor in rat brain synaptic membranes2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Synthesis and pharmacological evaluation of novel gamma-aminobutyric acid type B (GABAB) receptor agonists as gastroesophageal reflux inhibitors.
AID6363Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID40989Inhibition of [3H]- flunitrazepam binding to GABA-A benzodiazepine receptor at 10e-5 M1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
Phosphinic acid analogues of GABA. 1. New potent and selective GABAB agonists.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (62)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (24.19)18.2507
2000's37 (59.68)29.6817
2010's7 (11.29)24.3611
2020's3 (4.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
gamma-aminobutyric acid[no description available]medium230amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
baclofen[no description available]medium360amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
Arbaclofen[no description available]medium20organonitrogen compound;
organooxygen compound
3-aminopropylphosphonic acid[no description available]medium20phosphonic acids;
primary amino compound;
zwitterion		GABAB receptor agonist
3-aminopropylphosphinic acid[no description available]medium70
cgp 35348[no description available]medium90
cgp 36742[no description available]medium30
cgp 46381[no description available]medium20
aminolevulinic acid[no description available]medium104-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid		antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite
5-aminovaleric acid[no description available]medium10amino acid zwitterion;
delta-amino acid;
omega-amino fatty acid		human metabolite
gaboxadol[no description available]medium20oxazole
muscimol[no description available]medium50alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
(1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid[no description available]medium10
imidazoleacetic acid[no description available]medium30imidazoles;
monocarboxylic acid		metabolite;
mouse metabolite
4-aminocrotonic acid[no description available]medium20
n(4)-chloroacetylcytosine arabinoside[no description available]medium10
lesogaberan[no description available]medium20
cocaine[no description available]medium40benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
reserpine[no description available]medium20alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
sr 95531[no description available]medium20methoxybenzenes
bicuculline[no description available]medium120benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
organophosphonates[no description available]medium30divalent inorganic anion;
phosphite ion
cgp 54626[no description available]medium50
cgp 52432[no description available]medium70dichlorobenzene
cgp 52608[no description available]medium10thiazolidinone
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid[no description available]medium20non-proteinogenic alpha-amino acid
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
4-butyrolactone[no description available]medium40butan-4-olidemetabolite;
neurotoxin
sodium oxybate[no description available]medium50
ethyl methanesulfonate[no description available]medium10methanesulfonate esteralkylating agent;
antineoplastic agent;
carcinogenic agent;
genotoxin;
mutagen;
teratogenic agent
serine[no description available]medium10L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
picrotoxin[no description available]medium60
tyrosine[no description available]medium10amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
glycine[no description available]medium20alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
tryptophan[no description available]medium10erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
methanethiosulfonate[no description available]medium10
3,4-dihydroxyphenylglycol[no description available]medium10catechols;
tetrol		metabolite;
mouse metabolite
methoxyhydroxyphenylglycol[no description available]medium10methoxybenzenes;
phenols
kainic acid[no description available]medium10dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid[no description available]medium10polyamino carboxylic acid;
tetracarboxylic acid		chelator
ryanodine[no description available]medium10
inositol 1,4,5-trisphosphate[no description available]medium10myo-inositol trisphosphatemouse metabolite
egtazic acid[no description available]medium10diether;
tertiary amino compound;
tetracarboxylic acid		chelator
caffeine[no description available]medium10purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
glutamic acid[no description available]medium10glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
pinacidil[no description available]medium30pyridines
bradykinin[no description available]medium30oligopeptidehuman blood serum metabolite;
vasodilator agent
arachidonic acid[no description available]medium20icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
nitroglycerin[no description available]medium10nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
dithiothreitol[no description available]medium201,4-dimercaptobutane-2,3-diol;
butanediols;
dithiol;
glycol;
thiol		chelator;
human metabolite;
reducing agent
4-hydroxybutyric acid[no description available]medium104-hydroxy monocarboxylic acid;
hydroxybutyric acid		general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative
1-methyl-3-isobutylxanthine[no description available]medium103-isobutyl-1-methylxanthine
deoxyglucose[no description available]medium10
pentagastrin[no description available]medium10organic molecular entity
atropine[no description available]medium10
2-hydroxysaclofen[no description available]medium10organochlorine compound
gastrins[no description available]medium10
glyburide[no description available]medium10monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
meclofenamic acid[no description available]medium30aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
saclofen[no description available]medium30organochlorine compound
1,4-butanediol[no description available]medium20butanediol;
glycol		neurotoxin;
prodrug;
protic solvent
diazepam[no description available]medium101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
ncs 382[no description available]medium20
nicardipine[no description available]medium20benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
ornithine[no description available]medium20non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
n(g)-iminoethylornithine[no description available]medium20L-alpha-amino acid
flumazenil[no description available]medium10ethyl ester;
imidazobenzodiazepine;
organofluorine compound		antidote to benzodiazepine poisoning;
GABA antagonist
phaclofen[no description available]medium20organophosphate oxoanion;
zwitterion
cgp 7930[no description available]medium30alkylbenzene
pentylenetetrazole[no description available]medium10organic heterobicyclic compound;
organonitrogen heterocyclic compound
muscarine[no description available]medium10monosaccharide
strychnine[no description available]medium20monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
cgp 55845a[no description available]medium20
colforsin[no description available]medium10acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
isoproterenol[no description available]medium10catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
chlorine[no description available]medium10halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
azetidyl-2-carboxylic acid[no description available]medium10azetidine-2-carboxylic acid
quisqualic acid[no description available]medium10non-proteinogenic alpha-amino acid
azetidine-2,4-dicarboxylic acid[no description available]medium10
isradipine[no description available]medium10benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester
bay-k-8644[no description available]medium10(trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester
eosine yellowish-(ys)[no description available]medium10organic sodium salt;
organobromine compound		fluorochrome;
histological dye
cytarabine[no description available]medium10beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
cholecystokinin[no description available]medium10
iobenguane (131i)[no description available]medium10
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure0low10
Absence Seizures0low10
Acute Confusional Senile Dementia0low10
Alzheimer Dementia0low10
Alzheimer Disease0low10
Alzheimer Disease, Early Onset0low10
Alzheimer Disease, Late Onset0low10
Alzheimer Sclerosis0low10
Alzheimer Syndrome0low10
Alzheimer Type Senile Dementia0low10
Alzheimer-Type Dementia (ATD)0low10
Alzheimer's Disease0low10
Alzheimer's Disease, Focal Onset0low10
Alzheimer's Diseases0low10
Amnesia0low10
Amnesia-Memory Loss0low10
Amnesia, Dissociative0low10
Amnesia, Global0low10
Amnesia, Hysterical0low10
Amnesia, Tactile0low10
Amnesia, Temporary0low10
Amnestic State0low10
Anemia, Fanconi0low10
Anochlesia0low10
Atonic Absence Seizure0low10
Atonic Absence Seizures0low10
Atonic Seizure0low10
Atonic Seizures0low10
Aura0low20
Awakening Epilepsy0low20
Blood Pressure, High0low10
Bradykinesia0low10
Cancer of Intestines0low10
Cancer of the Intestines0low10
Catalepsy0low10
Cerea Flexibilitas0low10
Chemical Dependence0low10
Clonic Seizure0low10
Clonic Seizures0low10
Cocaine Abuse0low20
Cocaine Addiction0low20
Cocaine Dependence0low20
Cocaine-Related Disorders0low20
Complex Partial Seizure0low10
Complex Partial Seizures0low10
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Convulsion0low10
Convulsion, Non-Epileptic0low10
Convulsions0low10
Convulsive Seizure0low10
Convulsive Seizures0low10
Dementia, Alzheimer Type0low10
Dementia, Presenile0low10
Dementia, Primary Senile Degenerative0low10
Dementia, Senile0low10
Depression0low10
Disease Models, Animal0low70
Drug Abuse0low10
Drug Addiction0low10
Drug Dependence0low10
Drug Habituation0low10
Drug Use Disorders0low10
Early Onset Alzheimer Disease0low10
Epilepsy0low20
Epilepsy, Cryptogenic0low20
Epileptic Seizure0low10
Epileptic Seizures0low10
Esophageal Reflux0low20
Familial Alzheimer Disease (FAD)0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Fever, Zika0low10
Flexibility, Waxy0low10
Focal Onset Alzheimer's Disease0low10
Gastric Acid Reflux0low20
Gastric Acid Reflux Disease0low20
Gastro-Esophageal Reflux0low20
Gastro-Esophageal Reflux Disease0low20
Gastro-oesophageal Reflux0low20
Gastroesophageal Reflux0low20
Gastroesophageal Reflux Disease0low20
Gelineau Syndrome0low10
Gelineau's Syndrome0low10
Generalized Absence Seizure0low10
Generalized Absence Seizures0low10
Generalized Tonic-Clonic Seizures0low10
GERD0low20
Hypertension0low10
Hypodynamia0low10
Hypokinesia0low10
Hypokinesia, Antiorthostatic0low10
Hypothermia0low10
Hypothermia, Accidental0low10
Intestinal Cancer0low10
Intestinal Neoplasms0low10
Intestines Cancer0low10
Intestines Neoplasms0low10
Jacksonian Seizure0low10
Late Onset Alzheimer Disease0low10
Muscle Relaxation0low20
Myoclonic Seizure0low10
Myoclonic Seizures0low10
Narcolepsy0low10
Narcolepsy-Cataplexy Syndrome0low10
Narcoleptic Syndrome0low10
Neoplasms, Intestinal0low10
Neuroendocrine Tumors0low10
Non-Epileptic Seizure0low10
Non-Epileptic Seizures0low10
Nonepileptic Seizure0low10
Nonepileptic Seizures0low10
Organic Mental Disorders, Substance-Induced0low10
Paroxysmal Sleep0low10
Partial Seizure0low10
Partial Seizures0low10
Petit Mal Convulsion0low10
Pregnancy0low10
Prescription Drug Abuse0low10
Presenile Alzheimer Dementia0low10
Primary Senile Degenerative Dementia0low10
Reflux, Gastroesophageal0low20
Seizure0low10
Seizure Disorder0low20
Seizures0low10
Seizures, Auditory0low10
Seizures, Clonic0low10
Seizures, Convulsive0low10
Seizures, Epileptic0low10
Seizures, Focal0low10
Seizures, Generalized0low10
Seizures, Gustatory0low10
Seizures, Motor0low10
Seizures, Olfactory0low10
Seizures, Sensory0low10
Seizures, Somatosensory0low10
Seizures, Tonic0low10
Seizures, Tonic-Clonic0low10
Seizures, Vertiginous0low10
Seizures, Vestibular0low10
Seizures, Visual0low10
Senile Dementia, Acute Confusional0low10
Senile Dementia, Alzheimer Type0low10
Sensitivity and Specificity0low10
Single Seizure0low10
Substance Abuse0low10
Substance Addiction0low10
Substance Dependence0low10
Substance Use0low10
Substance Use Disorders0low10
Substance-Related Disorders0low10
Tonic Clonic Seizure0low10
Tonic Seizure0low10
Tonic Seizures0low10
Tonic-Clonic Seizure0low10
Tonic-Clonic Seizures0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Dosage (4)

ArticleYear
Behavioral effects of gamma-hydroxybutyrate, its precursor gamma-butyrolactone, and GABA(B) receptor agonists: time course and differential antagonism by the GABA(B) receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348).
The Journal of pharmacology and experimental therapeutics, Volume: 330, Issue: 3		2009
Effects of GABA(B) receptor antagonist, agonists and allosteric positive modulator on the cocaine-induced self-administration and drug discrimination.
European journal of pharmacology, Nov-28, Volume: 574, Issue: 2-3		2007
Cataleptic effects of gamma-hydroxybutyrate (GHB), its precursor gamma-butyrolactone (GBL), and GABAB receptor agonists in mice: differential antagonism by the GABAB receptor antagonist CGP35348.
Psychopharmacology, Volume: 192, Issue: 3		2007
Discriminative stimulus effects of flumazenil: perceptual masking by baclofen, and lack of substitution with gamma-hydroxybutyrate and its precursors 1,4-butanediol and gamma-butyrolactone.
Behavioural pharmacology, Volume: 17, Issue: 3		2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]